Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: autograft Clear all
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003399
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 25, 2026, 9:12 AM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 25, 2026, 9:12 AM EDT
Active, not recruiting Phase 3 Interventional

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 25, 2026, 9:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT02353572
View directory record Official record
Conditions
Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Melphalan, Bortezomib, Dexamethasone, Autologous Transplant
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Not applicable Interventional

The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures

NCT00582439
View directory record Official record
Conditions
Orthopaedic Trauma Fractures and Non-unions
Interventions
Reamer-Irrigator-Aspirator (RIA)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 1 Interventional

Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease

NCT00004294
View directory record Official record
Conditions
Gaucher's Disease
Interventions
human glucocerebrosidase gene into autologous peripheral blood stem cells
Genetic
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 9:12 AM EDT
Not listed Phase 1 Interventional

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

NCT01843686
View directory record Official record
Conditions
Acute Burns
Interventions
Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care
Device · Other
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Not applicable Interventional

Dural Graft Equivalent Comparison Trial

NCT01667770
View directory record Official record
Conditions
Chiari Malformation
Interventions
decompression of Chiari malformation
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 25, 2026, 9:12 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Not applicable Interventional

Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine

NCT01968993
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Interventions
nanOss Bioactive - posterolateral gutter
Device
Lead sponsor
Pioneer Surgical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 2 Interventional

Single- vs. Double-Bundle ACL Reconstruction

NCT01319409
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury
Interventions
Anatomic Double-Bundle ACL Reconstruction, Anatomic Single-Bundle ACL Reconstruction
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 25, 2026, 9:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation

NCT03943849
View directory record Official record
Conditions
Tooth Loss
Interventions
Particulate bone graft, Autogenous dental pulp tissue, Resorbable collagen membrane, Suture
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Sep 25, 2026, 9:12 AM EDT
Recruiting No phase listed Observational

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

NCT07662018
View directory record Official record
Conditions
Prospective Observational Study, Gemcitabine, Docetaxel, Melphalan, Carboplatin, Stem Cell Transplantation, Pediatric Relapsed, Refractory Germ
Interventions
Gemcitabine (GEM), Docetaxel, Melphalan, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Early Phase 1 Interventional

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

NCT04862676
View directory record Official record
Conditions
Myeloma
Interventions
Hyperbaric oxygen
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 2 Interventional

Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

NCT01130194
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Combination of treatment modalities
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 25, 2026, 9:12 AM EDT
Withdrawn Not applicable Interventional

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

NCT05482542
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
Other · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 58 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 25, 2026, 9:12 AM EDT
Not listed No phase listed Observational

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

NCT04896346
View directory record Official record
Conditions
Burn Scar, Scar
Interventions
Punch biopsy, non-invasive photography, assessments, and measurements
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine

NCT01087931
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine, Normal Saline
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 25, 2026, 9:12 AM EDT
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 25, 2026, 9:12 AM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Scleroderma: Cyclophosphamide or Transplantation

NCT00114530
View directory record Official record
Conditions
Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions
mHSCT, cyclophosphamide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Results available

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

NCT00225212
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma, Other Subtypes of B-cell Lymphoma, Lymphoma
Interventions
Rituximab 375 mg/m2
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 25, 2026, 9:12 AM EDT
Recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.

NCT06485206
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
One level Mobi-C and one level fusion
Device
Lead sponsor
Highridge Medical
Industry
Eligibility
22 Years to 69 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Sacramento, California • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 25, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Results available

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

NCT01045460
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 25, 2026, 9:12 AM EDT